New trial aims to outsmart cancer by adjusting chemo doses in real time

NCT ID NCT06525766

Recruiting now Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 2 times

Summary

This phase 2 trial tests whether giving the chemotherapy drug capecitabine in a flexible, response-based way (adaptive therapy) can better control metastatic ER-positive breast cancer. About 35 adults with advanced, hormone-resistant disease will receive doses that are adjusted based on tumor scans and blood markers. The goal is to see if this personalized dosing can slow tumor growth while reducing side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: capecitabine (Xeloda)
What this could lead to: If successful, this approach could offer a way to control metastatic breast cancer with fewer side effects by adjusting doses based on tumor response.
What could go wrong: This is a small, early-phase pilot study with only 35 participants. It may not show a clear benefit, and capecitabine can cause side effects like hand-foot syndrome and fatigue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE IV BREAST CANCER AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm estrogen-receptor positive breast cancer Her2-receptor negative breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANATOMIC STAGE IV BREAST CANCER AJCC V8 ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER METASTATIC BREAST CANCER METASTATIC HER2-NEGATIVE BREAST CARCINOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Mayo Clinic in Arizona
RECRUITING

Scottsdale, Arizona, 85259, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.